The surge in popularity of GLP-1 weight loss drugs, such as Ozempic, Wegovy, and Zepbound, has brought a new wave of patients to Long Island plastic surgeons. These medications, originally designed for diabetes management, have proven to be highly effective in aiding weight loss, but they also come with a unique set of challenges for patients and doctors alike. While many individuals seek cosmetic procedures to enhance their appearance post-weight loss, there are also medically necessary interventions. The article highlights a concerning trend: the significant skin sagging that can occur as a side effect of rapid weight loss. This issue is particularly prevalent among patients who have taken GLP-1 medications, leading to a surge in plastic surgery procedures on the island. The most notable side effect, dubbed 'Ozempic face', involves a gaunt, jowly appearance due to facial volume loss. However, the excess skin around the abdomen, breasts, thighs, and arms is a more widespread concern. According to the American Society of Plastic Surgeons, 20% of GLP-1 medication users have undergone plastic surgery, with 39% considering it and 41% contemplating non-surgical options. This trend has led to longer wait times for plastic surgery consultations, with some patients waiting up to a month. The article also highlights the challenges faced by women who have experienced significant weight fluctuations due to pregnancies, making it even harder for their bodies to recover. Dr. Kevin Small, a plastic surgeon, notes that the belly is a common concern, both aesthetically and functionally, as the excess skin can cause irritation and impact back and shoulder pain. The rapid weight loss associated with GLP-1 drugs can also lead to muscle wasting and core strength loss. Plastic surgeons are now seeing a diverse range of patients, including those who have lost weight through bariatric surgery and then regained it, only to lose more weight with GLP-1 medications. This complex scenario often requires reconstructive body contouring surgery, which is often covered by insurance as a medically necessary procedure. However, the use of GLP-1 medications in surgery poses a challenge: patients must discontinue their medication for two to three weeks before anesthesia-related procedures to avoid potential complications. The article emphasizes the importance of a holistic approach to weight loss, including exercise and good nutrition. Dr. David Pechman, director of bariatric surgery, stresses the benefits of resistance training and adequate protein intake to maintain muscle mass and elasticity. Lisa, a staff writer at Newsday, concludes by highlighting the transformative impact of these medications and the need for comprehensive support to ensure patients' long-term health and well-being.
